Literature DB >> 25697034

[Definitions and diagnosis of pulmonary hypertension].

Marius M Hoeper, Harm Jan Bogaard, Robin Condliffe, Robert Frantz, Dinesh Khanna, Marcin Kurzyna, David Langleben, Alessandra Manes, Toru Satoh, Fernando Torres, Martin R Wilkins, David B Badesch.   

Abstract

Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure 25 mm Hg at rest, measured during right heart catheterization. There is still insufficient .evidence to add an exercise criterion to this definition. The term pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure (PAWP) 15 mm Hg and a pulmonary vascular resistance >3 Wood units. Right heart catheterization remains essential for a diagnosis of PH or PAH. This procedure requires further standardization, including uniformity of the pressure transducer zero level at the midthoracic line, which is at the level of the left atrium. One of the most common problems in the diagnostic workup of patients with PH is the distinction between PAH and PH due to left heart failure with preserved ejection fraction (HFpEF). A normal PAWP does not rule out the presence of HFpEF. Volume or exercise challenge during right heart catheterization may be useful to unmask the presence of left heart disease, but both tools require further evaluation before their use in general practice can be recommended. Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing including diffusion capacity for carbon monoxide, biomarkers, and echocardiography has a higher predictive value than echocardiography alone. (J Am Coll Cardiol 2013;62: D42-50) ©2013 by the American College of Cardiology Foundation.

Entities:  

Year:  2014        PMID: 25697034

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  9 in total

Review 1.  Medical therapies for pulmonary arterial hypertension.

Authors:  Tomas Pulido; Nayeli Zayas; Maitane Alonso de Mendieta; Karen Plascencia; Jennifer Escobar
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  A novel rat model of pulmonary hypertension induced by mono treatment with SU5416.

Authors:  Yuqin Chen; Meidan Kuang; Shiyun Liu; Chi Hou; Xin Duan; Kai Yang; Wenjun He; Jing Liao; Qiuyu Zheng; Guofa Zou; Haixia Chen; Han Yan; Jiyuan Chen; Yi Li; Ying Zhou; Xiaoyun Luo; Qian Jiang; Haiyang Tang; Wenju Lu; Jian Wang
Journal:  Hypertens Res       Date:  2020-05-29       Impact factor: 3.872

Review 3.  Calcium-sensing receptor in the development and treatment of pulmonary hypertension.

Authors:  Ming-Yuan Zhou; Lin Cheng; Lei Chen; Ying-Jian Gu; Yun Wang
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

4.  Prediction of target genes for miR-140-5p in pulmonary arterial hypertension using bioinformatics methods.

Authors:  Fangwei Li; Wenhua Shi; Yixin Wan; Qingting Wang; Wei Feng; Xin Yan; Jian Wang; Limin Chai; Qianqian Zhang; Manxiang Li
Journal:  FEBS Open Bio       Date:  2017-10-21       Impact factor: 2.693

5.  Circulating sLR11 levels predict severity of pulmonary hypertension due to left heart disease.

Authors:  Yusuke Joki; Hakuoh Konishi; Hiroyuki Ebinuma; Kiyoshi Takasu; Tohru Minamino
Journal:  PLoS One       Date:  2021-12-29       Impact factor: 3.240

6.  Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography.

Authors:  Valentina Mercurio; Hussein J Hassan; Mario Naranjo; Alessandra Cuomo; Jeremy A Mazurek; Paul R Forfia; Aparna Balasubramanian; Catherine E Simpson; Rachel L Damico; Todd M Kolb; Stephen C Mathai; Steven Hsu; Monica Mukherjee; Paul M Hassoun
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

7.  Knockdown of AMPKα2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27(Kip1) Signaling Pathway.

Authors:  Rui Ke; Lu Liu; Yanting Zhu; Shaojun Li; Xinming Xie; Fangwei Li; Yang Song; Lan Yang; Li Gao; Manxiang Li
Journal:  Int J Mol Sci       Date:  2016-05-31       Impact factor: 5.923

8.  Prognostic impact of red blood cell distribution width in pulmonary hypertension patients: A systematic review and meta-analysis.

Authors:  Jie Liu; Jiao Yang; Shuanglan Xu; Yun Zhu; Shuangyan Xu; Li Wei; Panpan Qian; Yuanyuan Lv; Chunfang Zhang; Xiqian Xing; Yishu Deng
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

Review 9.  Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension.

Authors:  Yeganeh Abbasi; Javad Jabbari; Reza Jabbari; Charlotte Glinge; Seyed Bahador Izadyar; Edda Spiekerkoetter; Roham T Zamanian; Jørn Carlsen; Jacob Tfelt-Hansen
Journal:  Mol Genet Genomic Med       Date:  2018-08-06       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.